Brokerages predict that Mylan NV (NASDAQ:MYL) will report $1.29 earnings per share (EPS) for the current quarter, according to Zacks. Four analysts have provided estimates for Mylan’s earnings, with estimates ranging from $1.27 to $1.32. Mylan reported earnings of $1.30 per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 0.8%. The business is expected to report its next quarterly earnings report on Tuesday, February 25th.
According to Zacks, analysts expect that Mylan will report full year earnings of $4.31 per share for the current fiscal year, with EPS estimates ranging from $4.20 to $4.40. For the next fiscal year, analysts anticipate that the business will post earnings of $4.47 per share, with EPS estimates ranging from $4.30 to $4.67. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that cover Mylan.
Mylan (NASDAQ:MYL) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $1.17 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.14 by $0.03. Mylan had a return on equity of 18.80% and a net margin of 0.42%. The company had revenue of $2.96 billion during the quarter, compared to analyst estimates of $3.01 billion. During the same quarter in the previous year, the company posted $1.25 earnings per share. Mylan’s revenue was up 3.5% compared to the same quarter last year.
Several brokerages recently commented on MYL. ValuEngine raised Mylan from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 2nd. Mizuho lifted their price objective on Mylan from $25.00 to $27.00 and gave the stock a “neutral” rating in a report on Tuesday, July 30th. Cfra lowered Mylan from a “hold” rating to a “sell” rating in a report on Tuesday, November 5th. BidaskClub lowered Mylan from a “hold” rating to a “sell” rating in a report on Thursday, November 7th. Finally, Evercore ISI reaffirmed a “buy” rating on shares of Mylan in a report on Friday, August 9th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and eleven have assigned a buy rating to the company’s stock. Mylan currently has an average rating of “Hold” and an average price target of $27.97.
Shares of MYL traded up $0.04 during trading hours on Thursday, hitting $17.27. The stock had a trading volume of 5,291,138 shares, compared to its average volume of 6,651,576. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.43 and a quick ratio of 0.84. Mylan has a 12 month low of $16.63 and a 12 month high of $35.07. The firm has a market capitalization of $9.14 billion, a PE ratio of 3.77, a PEG ratio of 0.95 and a beta of 1.75. The stock has a fifty day moving average price of $18.53 and a 200 day moving average price of $19.32.
In other news, insider Goulds Bruce 8,000,000 shares of the firm’s stock in a transaction on Friday, November 8th. Insiders own 0.82% of the company’s stock.
Several institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of Mylan by 19.2% in the second quarter. Vanguard Group Inc. now owns 56,048,375 shares of the company’s stock valued at $1,067,160,000 after acquiring an additional 9,026,215 shares in the last quarter. Pzena Investment Management LLC lifted its position in shares of Mylan by 0.4% in the second quarter. Pzena Investment Management LLC now owns 21,103,981 shares of the company’s stock valued at $401,820,000 after acquiring an additional 76,305 shares in the last quarter. Invesco Ltd. lifted its position in shares of Mylan by 4.1% in the second quarter. Invesco Ltd. now owns 17,031,971 shares of the company’s stock valued at $324,289,000 after acquiring an additional 664,498 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Mylan by 11.0% in the second quarter. AQR Capital Management LLC now owns 11,247,227 shares of the company’s stock valued at $213,473,000 after acquiring an additional 1,111,009 shares in the last quarter. Finally, Menora Mivtachim Holdings LTD. lifted its position in shares of Mylan by 4.3% in the third quarter. Menora Mivtachim Holdings LTD. now owns 6,698,254 shares of the company’s stock worth $132,491,000 after buying an additional 277,000 shares in the last quarter. Institutional investors and hedge funds own 84.01% of the company’s stock.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Featured Article: Market Indexes
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.